Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Brendan Saloner, Barbara Andraka Christou, Adam J. Gordon & Bradley D. Stein. (2021) It will end in tiers: A strategy to include “dabblers” in the buprenorphine workforce after the X-waiver. Substance Abuse 42:2, pages 153-157.
Read now
Read now
Molly Doernberg$suffix/text()$suffix/text(), Noa Krawczyk$suffix/text()$suffix/text(), Deborah Agus$suffix/text()$suffix/text() & Michael Fingerhood$suffix/text()$suffix/text(). (2019) Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?. Substance Abuse 40:2, pages 148-153.
Read now
Read now
Adrian Miranda & Arturo Taca. (2018) Neuromodulation with percutaneous electrical nerve field stimulation is associated with reduction in signs and symptoms of opioid withdrawal: a multisite, retrospective assessment. The American Journal of Drug and Alcohol Abuse 44:1, pages 56-63.
Read now
Read now
Articles from other publishers (20)
Germán Gustavo Gornalusse, Lucia N. Vojtech, Claire N. Levy, Sean M. Hughes, Yeseul Kim, Rogelio Valdez, Urvashi Pandey, Christina Ochsenbauer, Rena Astronomo, Julie McElrath & Florian Hladik. (2021) Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency. Viruses 13:8, pages 1472.
Crossref
Crossref
Francisco Navarrete, María Salud García-Gutiérrez, Ani Gasparyan, Amaya Austrich-Olivares & Jorge Manzanares. (2021) Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders. Frontiers in Pharmacology 12.
Crossref
Crossref
Reda M. Chalhoub & Peter W. Kalivas. (2020) Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date. Drugs 80:15, pages 1509-1524.
Crossref
Crossref
Maria Carmen Blanco-Gandía, Sandra Montagud-Romero & Marta Rodríguez-Arias. 2020. Opioids - From Analgesic Use to Addiction. Opioids - From Analgesic Use to Addiction.
Theresa Winhusen, Michelle Lofwall, Hendrée E. Jones, Christine Wilder, Robert Lindblad, Davida M. Schiff, Scott Wexelblatt, Stephanie Merhar, Sean M. Murphy, Shelly F. Greenfield, Mishka Terplan, Elisha M. Wachman, Frankie Kropp, Jeff Theobald, Mitra Lewis, Abigail G. Matthews, Connie Guille, Michael Silverstein & Carmen Rosa. (2020) Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations. Contemporary Clinical Trials 93, pages 106014.
Crossref
Crossref
Tyler S. Oesterle, Bhanu Prakash Kolla, Teresa A. Rummans & Mark S. Gold. (2020) Medication-assisted therapies for opioid use disorders in patients with chronic pain. Journal of the Neurological Sciences 411, pages 116728.
Crossref
Crossref
Elizabeth A. Evans, Caroline Yoo, David Huang, Andrew J. Saxon & Yih-Ing Hser. (2019) Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder. Journal of Substance Abuse Treatment 106, pages 19-28.
Crossref
Crossref
Tyler S. Oesterle, Nuria J. Thusius, Teresa A. Rummans & Mark S. Gold. (2019) Medication-Assisted Treatment for Opioid-Use Disorder. Mayo Clinic Proceedings 94:10, pages 2072-2086.
Crossref
Crossref
Mehmet Sofuoglu, Elise E. DeVito & Kathleen M. Carroll. (2018) Pharmacological and Behavioral Treatment of Opioid Use Disorder. Psychiatric Research and Clinical Practice 1:1, pages 4-15.
Crossref
Crossref
Kathleen M. CarrollRoger D. Weiss. (2019) The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review. FOCUS 17:2, pages 183-192.
Crossref
Crossref
Teresa L. Mako, Joan M. Racicot & Mindy Levine. (2018) Supramolecular Luminescent Sensors. Chemical Reviews 119:1, pages 322-477.
Crossref
Crossref
C. Holly A. Andrilla, Tessa E. Moore & Davis G. Patterson. (2019) Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians. The Journal of Rural Health 35:1, pages 113-121.
Crossref
Crossref
M. Carmen Blanco-Gandía & Marta Rodríguez-Arias. (2018) Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years. European Journal of Pharmacology 836, pages 89-101.
Crossref
Crossref
Kai-Hsiang Kang, Li-Fen Kuo, I-Chen Cheng, Chih-Shiuh Chang & Wen-Ing Tsay. (2017) Trends in major opioid analgesic consumption in Taiwan, 2002–2014. Journal of the Formosan Medical Association 116:7, pages 529-535.
Crossref
Crossref
Maximilian Gahr, Jonas Eller, Maurice Cabanis, Christoph Hiemke, Roland W. Freudenmann, Bernhard J. Connemann, Dirk Lang & Carlos Schönfeldt-Lecuona. (2017) Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians. Journal of Substance Abuse Treatment 74, pages 7-15.
Crossref
Crossref
Milena Despotović, Mile Despotović, Hristos Aleksopulos, Jelena Aleksandrić & Nela Marinović. (2017) Influence of buprenorphine replacement therapy. Sestrinska rec 21:75, pages 12-15.
Crossref
Crossref
Gustavo A. Angarita, Nazli Emadi, Sarah Hodges & Peter T. Morgan. (2016) Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review. Addiction Science & Clinical Practice 11:1.
Crossref
Crossref
Tiffany Zhang. 2016. Peripheral Nerve Entrapments. Peripheral Nerve Entrapments
19
25
.
Daniel P. Alford, Lara Zisblatt, Pamela Ng, Sean M. Hayes, Sophie Peloquin, Ilana Hardesty & Julie L. White. (2015)
SCOPE
of Pain
: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program
. Pain Medicine, pages n/a-n/a.
Crossref
Crossref
Brandon G. Bergman, Bettina B. Hoeppner, Lindsay M. Nelson, Valerie Slaymaker & John F. Kelly. (2015) The effects of continuing care on emerging adult outcomes following residential addiction treatment. Drug and Alcohol Dependence 153, pages 207-214.
Crossref
Crossref